Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Epistemonikos ID: 3ab30ed2af7ee12b93a86b5c490cb6521870b6d2
First added on: May 08, 2024